PXMD vs. CYTO, NTBL, BPTS, ARDS, SNPX, KTRA, JAGX, PHAS, GNPX, and GOVX
Should you be buying PaxMedica stock or one of its competitors? The main competitors of PaxMedica include Altamira Therapeutics (CYTO), Notable Labs (NTBL), Biophytis (BPTS), Aridis Pharmaceuticals (ARDS), Synaptogenix (SNPX), Kintara Therapeutics (KTRA), Jaguar Health (JAGX), PhaseBio Pharmaceuticals (PHAS), Genprex (GNPX), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical preparations" industry.
PaxMedica (NASDAQ:PXMD) and Altamira Therapeutics (NASDAQ:CYTO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.
Altamira Therapeutics' return on equity of 0.00% beat PaxMedica's return on equity.
In the previous week, Altamira Therapeutics had 2 more articles in the media than PaxMedica. MarketBeat recorded 7 mentions for Altamira Therapeutics and 5 mentions for PaxMedica. PaxMedica's average media sentiment score of 0.33 beat Altamira Therapeutics' score of 0.13 indicating that PaxMedica is being referred to more favorably in the media.
PaxMedica has higher earnings, but lower revenue than Altamira Therapeutics.
PaxMedica presently has a consensus target price of $3.00, indicating a potential upside of 488.24%. Given PaxMedica's higher probable upside, equities research analysts clearly believe PaxMedica is more favorable than Altamira Therapeutics.
4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 1.9% of Altamira Therapeutics shares are owned by institutional investors. 57.9% of PaxMedica shares are owned by company insiders. Comparatively, 13.0% of Altamira Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
PaxMedica received 1 more outperform votes than Altamira Therapeutics when rated by MarketBeat users.
PaxMedica has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Altamira Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500.
Summary
PaxMedica beats Altamira Therapeutics on 7 of the 12 factors compared between the two stocks.
Get PaxMedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
PaxMedica Competitors List
Related Companies and Tools